Previous 10 | Next 10 |
Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update PR Newswire PUR1900 Phase 2b study dosed first patients in Q1 2023 PUR3100 Phase 1 study achieves positive topline results as announced in Q1 2023 $35.6 million in ...
Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma PR Newswire LEXINGTON, Mass. , Feb. 6, 2023 /PRNewswire/ -- Pulmatrix, Inc. ( NASDAQ : PULM ...
Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment" PR Newswire LEXINGTON, Mass. , Jan. 25, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutica...
Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology PR Newswire LEXINGTON, Mass. , Jan. 23, 2023 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company develo...
Nanocap pharma Pulmatrix, Inc. ( NASDAQ: PULM ) dropped ~18% in the morning hours Wednesday after announcing topline results from a Phase 1 trial for PUR3100, an orally inhaled dry powder formulation of dihydroergotamine (DHE) targeting acute migraine. The Australia-based study in...
Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine PR Newswire PUR3100 was safe and all doses had fewer GI side effects compared to IV DHE PUR3100 demonstrated a five-minut...
Pulmatrix press release ( NASDAQ: PULM ): Q3 GAAP EPS of -$1.45 beats by $0.06 . Revenue of $1.87M (+74.8% Y/Y) beats by $0.71M . For further details see: Pulmatrix GAAP EPS of -$1.45 beats by $0.06, revenue of $1.87M beats by $0.71M
Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update PR Newswire PUR1900 (Pulmazole) on track for Phase 2 study start in Q1 2023 PUR3100 Phase 1 study top line data anticipated in early Q1 2023 $40.7 million in cash...
Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine PR Newswire Company is evaluating its iSPERSE™ orally inhaled dry powder formulation of dihydroergotamine (DHE) for treatment of acute migraine and expects ph...
Pulmatrix press release ( NASDAQ: PULM ): Q2 GAAP EPS of -$1.36 beats by $0.15 . Revenue of $1.33M (-39.5% Y/Y) beats by $0.17M . Total cash and cash equivalents balance as of June 30, 2022 was $42.9 million. For further details see: Pulmatrix GAAP EP...
News, Short Squeeze, Breakout and More Instantly...
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) PR Newswire Orally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intravenously (IV) a...
Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update PR Newswire $16.3 million in cash and cash equivalents at the end of Q1 2024 providing projected cash runway into Q1 2026 Third amendment made in Q1 to Cipla partnership results ...